Clinical Trials
3 trialsNCT00283114 2014-12-18
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Seagen Inc.
Phase 1 Completed
NCT00002890 2013-06-25
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00502112 2011-10-12
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Seagen Inc.
Phase 1 Completed